Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Akcea Therapeutics, Inc. (NASDAQ: AKCA).

Full DD Report for AKCA

You must become a subscriber to view this report.


Recent News from (NASDAQ: AKCA)

Wired News - FDA's Advisory Committee Supports Approval of Akcea's WAYLIVRA(TM) for Treatment of Familial Chylomicronemia Syndrome
Stock Monitor: Biofrontera Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Akcea Therapeutics, Inc. (NASDAQ: AKCA) ("Akcea"), all you need to do is sign up now by clicking the following link www.active-investors.com/re...
Source: ACCESSWIRE IA
Date: May, 15 2018 07:30
Ionis And Akcea Obtain Positive Recommendation From Panel, Can They Go All The Way?
Recently, it was announced that Ionis Pharmaceuticals ( IONS ) and Akcea Therapeutics ( AKCA ) received a positive vote from the FDA advisory panel. This bodes well for FDA approval of volanesorsen, because the panel vote came in better than expected. The FDA doesn't have to listen to the ...
Source: SeekingAlpha
Date: May, 14 2018 02:44
Your Daily Pharma Scoop: Our Watchlist Pick ARMO Acquired, Ziopharma Low Cash, Coherus PDUFA Date
Analysis focus: ARMO Eli Lilly (NYSE: LLY ) has agreed to acquire ARMO BioSciences for $1.6bn ($50/share) in cash. This is almost a 40% premium to ARMO’s previous closing price of $29.82. It is currently trading at $49.80. The transaction will close this quarter, helping Lilly bol...
Source: SeekingAlpha
Date: May, 11 2018 10:00
Ionis and Akcea up premarket after Ad Com vote
Ionis Pharmaceuticals (NASDAQ: IONS ) and affiliate Akcea Therapeutics (NASDAQ: AKCA ) are up  3%  and  16% , respectively, in light premarket trade after an FDA Ad Com voted 12 - 8 backing volanesoren, branded as WAYLIVRA, for familial chylomicronemia syndrome. More news on...
Source: SeekingAlpha
Date: May, 11 2018 08:08
FDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia Syndrome
CAMBRIDGE, Mass. and CARLSBAD, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the U.S. Food and Drug Administration’s (FDA) Division of Me...
Source: GlobeNewswire
Date: May, 10 2018 18:21
FDA Ad Com renders split vote on Akcea's volanesoren
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 12 - 8 that Akcea Therapeutics' (NASDAQ: AKCA ) volanesoren should be approved in the U.S. More news on: Akcea Therapeutics, Ionis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 10 2018 17:02
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akcea Therapeutics, Inc. - AKCA
NEW YORK , May 10, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Akcea Therapeutics, Inc. ("Akcea" or the "Company") (NASDAQ: AKCA).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com ...
Source: PR Newswire
Date: May, 10 2018 14:38
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akcea Therapeutics, Inc. (AKCA)
NEW YORK , May 10, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akcea Therapeutics, Inc. ("Akcea" or the "Company")  (NASDAQ: AKCA). Such investors are encouraged to obtain a...
Source: PR Newswire
Date: May, 10 2018 10:57
Biotech Analysis Central Pharma News: Takeda's Acquisition Win, Ionis And Akcea Tumble, Alnylam's Advance In CNS
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Takeda Acquires Shire For $62 Billion News: It was announced recently that Takeda ( TKPYY ) would pay $62 billion in total to acquire rare disea...
Source: SeekingAlpha
Date: May, 09 2018 01:40
Premarket Losers as of 9:05 am (5/8/2018)
ARLZ   -26%  on terminating U.S. operations. More news on: Aralez Pharmaceuticals Inc., Nevro, Nobilis Health Corp., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 08 2018 09:19

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1722.7122.9323.01522.64142,101

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1329,74642,35070.2385Short
2018-08-1091,205139,03165.6005Short
2018-08-0934,46644,49077.4691Short
2018-08-0868,30498,75769.1637Short
2018-08-07211,699366,41957.7751Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AKCA.


About Akcea Therapeutics, Inc. (NASDAQ: AKCA)

Logo for Akcea Therapeutics, Inc. (NASDAQ: AKCA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: AKCA)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 07 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: April, 26 2018
      All other definitive information statements
      Filing Type: DEF 14CFiling Source: edgar
      Filing Date: April, 20 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 20 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 17 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 06 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: March, 28 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: March, 26 2018

       

       


      Daily Technical Chart for (NASDAQ: AKCA)

      Daily Technical Chart for (NASDAQ: AKCA)


      Stay tuned for daily updates and more on (NASDAQ: AKCA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: AKCA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AKCA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AKCA and does not buy, sell, or trade any shares of AKCA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/